Serum Level of Antibodies (IgG, IgM) Against Benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA Adducts in Children Dermatologically Exposed to Coal Tar
Language English Country Czech Republic Media print-electronic
Document type Journal Article
PubMed
28467299
DOI
10.14712/18059694.2017.46
PII: 18059694.2017.46
Knihovny.cz E-resources
- Keywords
- BPDE-DNA adducts, antibodies, children, coal tar, goeckerman therapy, polycyclic aromatic hydrocarbons, psoriasis,
- MeSH
- 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide analysis MeSH
- DNA Adducts blood drug effects MeSH
- Coal Tar adverse effects therapeutic use MeSH
- Child MeSH
- Keratolytic Agents administration & dosage therapeutic use MeSH
- Humans MeSH
- DNA Damage drug effects MeSH
- Child, Preschool MeSH
- Psoriasis drug therapy MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Child, Preschool MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide MeSH
- DNA Adducts MeSH
- Coal Tar MeSH
- Keratolytic Agents MeSH
Crude coal tar (CCT) contains polycyclic aromatic hydrocarbons (PAHs). Benzo[a]pyrene (BaP) is metabolized into a highly reactive metabolite benzo[a]pyrene-7,8-diol-9,10-epoxide (BPDE) that is able to bind to DNA and creates BPDE-DNA adducts. Adducted DNA becomes immunogenic and induces immune response by production of antibodies against BPDE-DNA adducts (Ab-BPDE-DNA). Circulating Ab-BPDE-DNA was proposed as potential biomarker of genotoxic exposure to BaP (PAHs). Goeckerman therapy (GT) of psoriasis uses dermal application of CCT ointment (PAHs). In presented study (children with psoriasis treated by GT; n = 19) the therapy significantly increased the level of Ab-BPDE-DNA (EI = 0.29/0.19-0.34 vs. 0.31/0.25-0.40; median/lower-upper quartile; p < 0.01). The results support the idea of Ab-BPDE-DNA level as a possible tentative indicator of exposure, effects and susceptibility of the organism to the exposure of BaP (PAHs).
References provided by Crossref.org
